Tempest Therapeutics Inc (TPST)

$2.40 -0.03 (-1.23%)
Market Cap 11.83M
Revenue (ttm) 0.00
Net Income (ttm) -41.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 40,200
Avg Vol 101,346
Day's Range N/A - N/A
Shares Out 4.93M
Stochastic %K 80%
Beta -2.48
Analysts Strong Sell
Price Target $10.50

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 798 8589
Address:
2000 Sierra Point Parkway, Suite 400, Brisbane, United States
Michl2000
Michl2000 Feb. 23 at 5:20 PM
$TPST $SLS
0 · Reply
lousjamsession
lousjamsession Feb. 23 at 2:27 PM
$TPST halt lol jk
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 22 at 9:34 PM
$TPST In my opinion, Buying Shares before Warrants is just plain stupid anyway. Why? If Share Price goes Down, then Warrant Price usually FALL more. However, if Share Price goes UP then Warrant Price Rises MORE. Why else do you think the Volume is SO LOW? We're following good Business Practices. I Sold ALL my Shares in preparation. Also, I'd like to Buy more Warrants, FIRST, before Shares again.
2 · Reply
My_Lai_1968
My_Lai_1968 Feb. 22 at 9:18 PM
$TPST This company has everything you look for in a stock. If you're shorting it, that is.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 22 at 5:58 AM
$TPST I hope NASDAQ agrees that we shall have our TPST Public Warrants by March 5th.
1 · Reply
lousjamsession
lousjamsession Feb. 21 at 9:27 PM
$TPST
2 · Reply
lousjamsession
lousjamsession Feb. 21 at 8:26 PM
$TPST
2 · Reply
claybridge
claybridge Feb. 21 at 4:02 PM
$TPST this individual does the heavy lifting for us. Everyone needs to read his/her posts closely. We've been speculating about the warrants distribution for weeks and we've had our answer since January 20th. The warrants won't be distributed until we get the 10K. The 10K can drop any day, but they have until March 31st. You guys can speculate all you want, but there is a HIGH probability that nothing major is coming prior to warrant distribution. All bullish speculation to this point has been dead wrong. We have to be patient now and let Angel execute.
1 · Reply
lousjamsession
lousjamsession Feb. 21 at 2:50 PM
$TPST no volume. Looks like the bottom. Where the warrants? Sneaky catalyst.
3 · Reply
We_Like_daStooooock
We_Like_daStooooock Feb. 20 at 10:58 PM
$TPST Holding for dumb luck for this thing to appreciate.
0 · Reply
Latest News on TPST
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Feb 11, 2026, 6:59 AM EST - 12 days ago

Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Feb 4, 2026, 4:47 PM EST - 18 days ago

Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Jan 20, 2026, 5:20 PM EST - 4 weeks ago

Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 26, 2025, 4:05 PM EST - 3 months ago

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Nov 25, 2025, 8:00 AM EST - 3 months ago

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

Nov 19, 2025, 9:00 AM EST - 3 months ago

Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

BTX

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 8:30 AM EST - 3 months ago

Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:12 PM EDT - 6 months ago

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 30, 2025, 8:00 AM EDT - 8 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 11, 2025, 8:00 AM EDT - 9 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Jun 5, 2025, 8:00 AM EDT - 9 months ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:28 PM EDT - 10 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 28, 2025, 4:05 PM EDT - 10 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 21, 2025, 8:00 AM EDT - 11 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Apr 9, 2025, 4:30 PM EDT - 11 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 27, 2025, 4:10 PM EDT - 11 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 25, 2025, 4:30 PM EDT - 11 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Mar 13, 2025, 8:00 AM EDT - 1 year ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 10, 2025, 8:00 AM EST - 1 year ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:30 PM EST - 1 year ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Jan 6, 2025, 8:00 AM EST - 1 year ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 4:30 PM EST - 1 year ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 12, 2024, 4:21 PM EST - 1 year ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 9:06 AM EDT - 1 year ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 17, 2024, 1:26 PM EDT - 2 years ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 9, 2024, 8:00 AM EDT - 2 years ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Apr 4, 2024, 8:00 AM EDT - 2 years ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 19, 2024, 4:25 PM EDT - 2 years ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Mar 5, 2024, 4:30 PM EST - 2 years ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Tempest Therapeutics shares end wild week with 8% drop

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Oct 10, 2023, 4:05 PM EDT - 2 years ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

Tempest to Present at the Jefferies Global Healthcare Conference

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

Michl2000
Michl2000 Feb. 23 at 5:20 PM
$TPST $SLS
0 · Reply
lousjamsession
lousjamsession Feb. 23 at 2:27 PM
$TPST halt lol jk
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 22 at 9:34 PM
$TPST In my opinion, Buying Shares before Warrants is just plain stupid anyway. Why? If Share Price goes Down, then Warrant Price usually FALL more. However, if Share Price goes UP then Warrant Price Rises MORE. Why else do you think the Volume is SO LOW? We're following good Business Practices. I Sold ALL my Shares in preparation. Also, I'd like to Buy more Warrants, FIRST, before Shares again.
2 · Reply
My_Lai_1968
My_Lai_1968 Feb. 22 at 9:18 PM
$TPST This company has everything you look for in a stock. If you're shorting it, that is.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Feb. 22 at 5:58 AM
$TPST I hope NASDAQ agrees that we shall have our TPST Public Warrants by March 5th.
1 · Reply
lousjamsession
lousjamsession Feb. 21 at 9:27 PM
$TPST
2 · Reply
lousjamsession
lousjamsession Feb. 21 at 8:26 PM
$TPST
2 · Reply
claybridge
claybridge Feb. 21 at 4:02 PM
$TPST this individual does the heavy lifting for us. Everyone needs to read his/her posts closely. We've been speculating about the warrants distribution for weeks and we've had our answer since January 20th. The warrants won't be distributed until we get the 10K. The 10K can drop any day, but they have until March 31st. You guys can speculate all you want, but there is a HIGH probability that nothing major is coming prior to warrant distribution. All bullish speculation to this point has been dead wrong. We have to be patient now and let Angel execute.
1 · Reply
lousjamsession
lousjamsession Feb. 21 at 2:50 PM
$TPST no volume. Looks like the bottom. Where the warrants? Sneaky catalyst.
3 · Reply
We_Like_daStooooock
We_Like_daStooooock Feb. 20 at 10:58 PM
$TPST Holding for dumb luck for this thing to appreciate.
0 · Reply
claybridge
claybridge Feb. 20 at 7:33 PM
$TPST
0 · Reply
lousjamsession
lousjamsession Feb. 20 at 4:00 PM
$TPST
0 · Reply
brunoq14
brunoq14 Feb. 20 at 3:45 PM
$TPST Company's drugs were endorsed by FDA and NHI. Now worth virtually nothing.
2 · Reply
fantastex
fantastex Feb. 20 at 10:11 AM
$TPST wtf
2 · Reply
fantastex
fantastex Feb. 19 at 11:31 PM
$TPST would they pump this to 20 withiut issuing the warrants First ? 🤔🤔
2 · Reply
Wizard714
Wizard714 Feb. 19 at 11:23 PM
$TPST This thing is going to $0.
0 · Reply
PennyScam
PennyScam Feb. 19 at 8:03 PM
$TPST Don’t worry Bruno. Shareholders still have plenty of time to jump in. I suggest keep growing your rights and stop worrying about things that are out of your control. The rights party has been extended. I’m loving it. Be happy. Don’t you love a good extension. Good times. 👍 Crazy K
0 · Reply
lousjamsession
lousjamsession Feb. 19 at 4:07 PM
$TPST
0 · Reply
brunoq14
brunoq14 Feb. 19 at 12:38 PM
$TPST Someone should get smacked for what happened to shareholders here. Unloaded my few remaining shares, modest loss, never made large bet.
0 · Reply
joeyknowie
joeyknowie Feb. 19 at 12:16 PM
$TPST it’s interesting that apparently the warrant registration won’t be filed until after the late March 10k. I have no idea why except it seems this was planned out ahead of time so there seems to be a reason behind it. What the reason is I have no idea at all.
0 · Reply
Onedaytolive
Onedaytolive Feb. 19 at 11:00 AM
$TPST My Webull account is already at $0 lol If you're worried, you should sell quickly. I'll gladly buy it cheap lol
0 · Reply
saddy12345
saddy12345 Feb. 19 at 8:33 AM
$TPST Why people are buying this trash? It's goin to 0. Wake up!
0 · Reply